Targeted Therapy Technologies, LLC (3T Ophthalmics) is an innovative biotechnology company based in Irvine, CA, specializing in less invasive ocular drug delivery for the treatment of various ocular diseases. Their proprietary technology allows for the targeted delivery of therapeutic agents without the need to penetrate the eye, offering potential solutions for neoplastic, inflammatory, neovascular, and neurodegenerative ocular conditions.
3T Ophthalmics has recently received FDA Breakthrough Therapy Designation for their lead anti-cancer drug candidate, Episcleral Topotecan, specifically developed for the treatment of pediatric Retinoblastoma. This designation recognizes the drug's potential to significantly improve upon existing therapies and may expedite its development and regulatory review process. With a focus on saving eyes and restoring vision, 3T Ophthalmics is committed to providing reliable and simplified treatment options for Retinoblastoma patients.
Generated from the website